BIOINFOGATE TO PRESENT AT THE CHEM-BIO INFORMATICS SOCIETY (CBI) ANNUAL MEETING (TOKYO, JAPAN, OCTOBER 22-24, 2019)
Bioinfogate has been invited to a speak at the Chem-Bio Informatics Society (CBI) Annual Meeting "Towards Seamless Integration of Structural Biology and Information Science"～Dawn of the AI era in drug discovery～" which takes place in Tokyo, Oct. 22-24, 2019.
During the Focused Session FS13 "Computational toxicology – practical and application", (Wed Oct. 23, 16:00-17:30), Dr Josep Prous, Jr., Executive Director at Bioinfogate will present “THE IMPORTANCE OF A SOLID KNOWLEDGE MANAGEMENT STRATEGY IN COMPUTATIONAL TOXICOLOGY”.
Given the continuous growth of safety and toxicity information, it is essential to design an adequate knowledge management plan to identify the most relevant safety hotspots to be analyzed in the context of a research project.
In his presentation, Dr Prous, Jr. will explain how the availability of a large amount of high quality, manually curated information has allowed scoring functions to be developed in order to identify safety hotspots which may be readily applicable in computational toxicology programs.
This approach has been integrated into the OFF-X translational safety intelligence portal which provides integrated preclinical toxicity and clinical adverse event intelligence for drugs and targets in all phases of drug R&D, including first-in-class and emerging targets.
For further information or to schedule a meeting during the conference, please contact firstname.lastname@example.org.
About the Chem-Bio Informatics Society
The Chem-BioInformatics (CBI) Society is a Japanese non-profit organization that aims to provide a platform for promoting cutting-edge interdisciplinary areas related to chemistry, biology, and informatics. The CBI Society is interested in molecular recognition and molecular modeling, in silico drug discovery, bioinformatics and their applications in medicine, information and computing approaches for drug design and ADMET studies, and emerging new technologies.
Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and also identifying and investing in emerging projects that align with our core business in the life sciences and data analytics.
Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007), acquired by Thomson Reuters in 2007 (now Clarivate Analytics), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.
LAUNCH OF BIOINFOGATE’S OFF-X TRANSLATABILITY DASHBOARD
The Translatability Dashboard supports understanding of how toxicity events derived from experimental assays and animal models translate to the clinic
Jul 23 ,2020
FDA AND BIOINFOGATE AGREE TO EXTEND THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL
The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.
May 26 ,2020
BIOINFOGATE’S OFF-X PROVIDES A DEDICATED “COVID-19” SECTION
The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.
Apr 02 ,2020